Effects of a combination of puerarin, baicalin and berberine on the expression of proliferator-activated receptor-γ and insulin receptor in a rat model of nonalcoholic fatty liver disease

Zhao,Weihan; Liu,Lijuan; Wang,Yunliang; Mao,Tangyou; Li,Junxiang

doi:10.3892/etm.2015.2846

Effects of a combination of puerarin, baicalin and berberine on the expression of proliferator-activated receptor-γ and insulin receptor in a rat model of nonalcoholic fatty liver disease

Authors:
- Weihan Zhao
- Lijuan Liu
- Yunliang Wang
- Tangyou Mao
- Junxiang Li
View Affiliations

Affiliations: Gastroenterology Department, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing 100078, P.R. China
Published online on: November 9, 2015 https://doi.org/10.3892/etm.2015.2846
Pages: 183-190

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a prevalent disease, with a clinical spectrum ranging from simple fatty liver disease to nonalcoholic steatohepatitis and cirrhosis. Puerarin, baicalin and berberine are herbal products widely used in Asia, which are believed to possess therapeutic benefits for alleviating the symptoms of NAFLD. In the present study, a rat model of NAFLD, induced by a high‑fat diet, was established and orthographical experimentation was used to investigate the effects of various combinations of puerarin, baicalin and berberine on the hepatic expression of proliferator‑activated receptor (PPAR)‑γ and insulin receptor (IR). The present study demonstrated that serum levels of total cholesterol, alanine transaminase and low‑density lipoproteins were significantly decreased in the puerarin‑dominated groups (P<0.05 vs. the model group), whereas the concentrations of tumor necrosis factor‑α and interleukin‑6 were significantly improved in the baicalin‑ and berberine‑dominated groups (P<0.05 vs. the model group). Furthermore, as compared with the control group, the levels of PPAR‑γ/IR mRNA and protein expression were significantly decreased in the model group (P<0.01), and significantly increased in the rosiglitazone group and some of the orthogonal experiment groups (P<0.01). In conclusion, a combination of puerarin, baicalin and berberine induced favorable effects on NAFLD by upregulating hepatic PPAR‑γ and IR expression levels, and different proportions of monomer compositions exerted variable positive effects on various stages of NAFLD.

View Figures

View References

1	Marchesini G and Marzocchi R: Metabolic syndrome and NASH. Clin Liver Dis. 11105–117. (ix)2007. View Article : Google Scholar : PubMed/NCBI
2	Fabbrini E, Sullivan S and Klein S: Obesity and nonalcoholic fatty liver disease: Biochemical, metabolic and clinical implications. Hepatology. 51:679–689. 2010. View Article : Google Scholar : PubMed/NCBI
3	Song HY, Zhang L, Pan JL, Yang LL and Ji G: Bioactivity of five components of Chinese herbal formula Jiangzhi granules against hepatocellular steatosis. J Integr Med. 11:262–268. 2013. View Article : Google Scholar : PubMed/NCBI
4	Stein LL, Dong MH and Loomba R: Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status. Adv Ther. 26:893–907. 2009. View Article : Google Scholar : PubMed/NCBI
5	Sun L and Lü SZ: Association between non-alcoholic fatty liver disease and coronary artery disease severity. Chin Med J (Engl). 124:867–872. 2011.PubMed/NCBI
6	Zhao JS, Zhu FS, Liu S, Yang CQ and Chen XM: Pioglitazone ameliorates nonalcoholic steatohepatitis by down-regulating hepatic nuclear factor-kappa B and cyclooxygenases-2 expression in rats. Chin Med J (Engl). 125:2316–2321. 2012.PubMed/NCBI
7	Zhao CY, Jiang LL, Li L, Deng ZJ, Liang BL and Li JM: Peroxisome proliferator activated receptor-gamma in pathogenesis of experimental fatty liver disease. World J Gastroenterol. 10:1329–1332. 2004.PubMed/NCBI
8	Nan YM, Fu N, Wu WJ, Liang BL, Wang RQ, Zhao SX, Zhao JM and Yu J: Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice. Scand J Gastroenterol. 44:358–365. 2009. View Article : Google Scholar : PubMed/NCBI
9	Lutchman G, Modi A, Kleiner DE, Promrat K, Heller T, Ghany M, Borg B, Loomba R, Liang TJ and Premkumar A: The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology. 46:424–429. 2007. View Article : Google Scholar : PubMed/NCBI
10	Chiu SL and Cline HT: Insulin receptor signaling in the development of neuronal structure and function. Neural Dev. 5:72010. View Article : Google Scholar : PubMed/NCBI
11	Zhang Q, Xiao XH, Li M, Li WH, Yu M, Zhang HB, Ping F, Wang ZX and Zheng J: Chromium-containing traditional Chinese medicine, Tianmai Xiaoke Tablet improves blood glucose through activating insulin-signaling pathway and inhibiting PTP1B and PCK2 in diabetic rats. J Integr Med. 12:162–170. 2014. View Article : Google Scholar : PubMed/NCBI
12	Samuel VT and Shulman GI: Integrating mechanisms for insulin resistance: Common threads and missing links. Cell. 148:852–8712012. View Article : Google Scholar
13	Mohammadi A, Gholamhoseinian A and Fallah H: Zataria multiflora increases insulin sensitivity and PPAR-γ gene expression in high fructose fed insulin resistant rats. Iran J Basic Med Sci. 17:263–270. 2014.PubMed/NCBI
14	Rani S and O'Driscoll L: Analysis of changes in phosphorylation of receptor tyrosine kinases: Antibody arrays. Methods Mol Biol. 1233:15–23. 2015. View Article : Google Scholar : PubMed/NCBI
15	Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, Doo E, Ghany M, Premkumar A, Park Y, et al: A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology. 39:188–196. 2004. View Article : Google Scholar : PubMed/NCBI
16	Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, et al: Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care. 27:256–263. 2004. View Article : Google Scholar : PubMed/NCBI
17	Parulkar AA, Pendergrass ML, Granda-Ayala R, Lee TR and Fonseca VA: Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med. 134:61–71. 2001. View Article : Google Scholar : PubMed/NCBI
18	Wang WJ: Enhancing the treatment of metabolic syndrome with integrative medicine. J Integr Med. 11:153–156. 2013. View Article : Google Scholar : PubMed/NCBI
19	Yao Z, Zhang L and Ji G: Efficacy of polyphenolic ingredients of Chinese herbs in treating dyslipidemia of metabolic syndromes. J Integr Med. 12:135–146. 2014. View Article : Google Scholar : PubMed/NCBI
20	Wang Y and Li J, Zhuge L, Su D, Yang M, Tao S and Li J: Comparison between the efficacies of curcumin and puerarin in C57BL/6 mice with steatohepatitis induced by a methionine- and choline-deficient diet. Exp Ther Med. 7:663–668. 2014.PubMed/NCBI
21	Guo HX, Liu DH, Ma Y, Liu JF, Wang Y, Du ZY, Wang X, Shen JK and Peng HL: Long-term baicalin administration ameliorates metabolic disorders and hepatic steatosis in rats given a high-fat diet. Acta Pharmacol Sin. 30:1505–1512. 2009. View Article : Google Scholar : PubMed/NCBI
22	Chang X, Yan H, Fei J, Jiang M, Zhu H, Lu D and Gao X: Berberine reduces methylation of the MTTP promoter and alleviates fatty liver induced by a high-fat diet in rats. J Lipid Res. 51:2504–2515. 2010. View Article : Google Scholar : PubMed/NCBI
23	Cui W, Li X, Zhou S and Weng J: Investigation on process parameters of electrospinning system through orthogonal experimental design. J Appl Polym Sci. 103:3105–3112. 2007. View Article : Google Scholar
24	Khan F, Choong WL, Du Q and Jovanovi'c A: Real-time RT-PCR Ct values for blood GAPDH correlate with measures of vascular endothelial function in humans. Clin Transl Sci. 6:481–484. 2013. View Article : Google Scholar : PubMed/NCBI
25	Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC and McCullough AJ: Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology. 116:1413–1419. 1999. View Article : Google Scholar : PubMed/NCBI
26	Adams LA and Angulo P: Treatment of non-alcoholic fatty liver disease. Postgrad Med J. 82:315–322. 2006. View Article : Google Scholar : PubMed/NCBI
27	Day CP and James OF: Steatohepatitis: A tale of two ‘hits’? Gastroenterology. 114:842–845. 1998. View Article : Google Scholar : PubMed/NCBI
28	Postic C and Girard J: Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: Lessons from genetically engineered mice. J Clin Invest. 118:829–838. 2008. View Article : Google Scholar : PubMed/NCBI
29	Law RE, Goetze S, Xi XP, Jackson S, Kawano Y, Demer L, Fishbein MC, Meehan WP and Hsueh WA: Expression and function of PPARgamma in rat and human vascular smooth muscle cells. Circulation. 101:1311–1318. 2000. View Article : Google Scholar : PubMed/NCBI
30	Harrison SA: Thiazolidinedione therapy for nonalcoholic steatohepatitis: Go, stop, or proceed with caution? Hepatology. 51:366–369. 2010. View Article : Google Scholar : PubMed/NCBI
31	Nan YM, Fu N, Wu WJ, Liang BL, Wang RQ, Zhao SX, Zhao JM and Yu J: Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice. Scand J Gastroenterol. 44:358–365. 2009. View Article : Google Scholar : PubMed/NCBI
32	Cheatham B and Kahn CR: Cysteine 647 in the insulin receptor is required for normal covalent interaction between alpha-andbeta-subunits and signal transduction. J Biol Chem. 267:7108–7115. 1992.PubMed/NCBI
33	Seino S and Bell GI: Alternative splicing of human insulin receptor messenger RNA. Biochem Biophys Res Commun. 159:312–316. 1989. View Article : Google Scholar : PubMed/NCBI
34	El-Bassossy HM, Abo-Warda SM and Fahmy A: Chrysin and luteolin alleviate vascular complications associated with insulin resistance mainly through PPAR-γ activation. Am J Chin Med. 42:1153–1167. 2014. View Article : Google Scholar : PubMed/NCBI
35	Shamsi BH, Ma C, Naqvi S and Xiao Y: Effects of pioglitazone mediated activation of PPAR-γ on CIDEC and obesity related changes in mice. PLoS One. 9:e1069922014. View Article : Google Scholar : PubMed/NCBI
36	Wang RC and Jiang DM: PPAR-γ agonist pioglitazone affects rat gouty arthritis by regulating cytokines. Genet Mol Res. 13:6577–6781. 2014. View Article : Google Scholar : PubMed/NCBI
37	Seeff LB, Lindsay KL, Bacon BR, Kresina TF and Hoofnagle JH: Complementary and alternative medicine in chronic liver disease. Hepatology. 34:595–603. 2001. View Article : Google Scholar : PubMed/NCBI
38	Liu RJ, Zhang YW, Wen CW and Tang J: Study on the design and analysis methods of orthogonal experiment. Exp Technol and Manage. 27:52–552010.
39	Silva RN, Bueno PG, Avó LR, Nonaka KO, Selistre-Araújo HS and Leal AM: Effect of physical training on liver expression of activin A and follistatin in a nonalcoholic fatty liver disease model in rats. Braz J Med Biol Res. 47:746–752. 2014. View Article : Google Scholar : PubMed/NCBI
40	Kucera O and Cervinkova Z: Experimental models of non-alcoholic fatty liver disease in rats. World J Gastroenterol. 20:8364–8376. 2014. View Article : Google Scholar : PubMed/NCBI